Alnylam Pharmaceuticals is highlighted as a leader in the oligonucleotides market, particularly in RNA interference therapies. It is named among 'Unstoppable Stocks to Buy and Hold for the Next 3 Years.' A Canaccord Genuity analyst maintained a Buy rating on the stock. While the share price has declined 16.8% year-to-date, it has delivered strong long-term returns of 64.3% over three years and 132.1% over five years, reflecting confidence in its innovative pipeline and market position.